Akeso and Summit Therapeutics moved to reinforce the clinical case for ivonescimab with new HARMONi-2 results presented at the World Conference on Lung Cancer. The dual-acting PD-1/VEGF antibody-delivered program showed a survival benefit versus Merck’s Keytruda in Phase 3 lung cancer data, with overall survival showing a 27% lower relative risk of death (median 30.8 vs. 22.6 months; benefit in the broadly analyzed population). Akeso and Summit also highlighted stronger outcomes in a subset of patients whose tumors express high levels of PD-L1, where the relative risk reduction reached 42% compared with Keytruda. The updates are aimed at countering earlier market concerns about whether China-based trial execution would translate across global populations. The companies have already gained approval in China and positioned HARMONi-7 as a key next Phase 3 readout for the high-PD-L1 group—an important decision point for whether ivonescimab can challenge Keytruda as a lung-cancer backbone.